MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/72.5/0.1/20.06.25 | Market Closed - Börse Stuttgart 02:23:04 2024-07-11 pm EDT | ||
| 1.02 EUR | +2.00% |
|
| Current month | -9.73% | ||
| 1 month | -15.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.02 | +2.00% |
| 24-07-10 | 1 | +6.38% |
| 24-07-09 | 0.94 | -3.09% |
| 24-07-08 | 0.97 | -2.02% |
| 24-07-05 | 0.99 | -3.88% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 02:23 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME3JA2 |
| ISIN | DE000ME3JA24 |
| Date issued | 2023-11-13 |
| Strike | 72.5 $ |
| Maturity | 2025-06-20 (344 Days) |
| Parity | 10 : 1 |
| Emission price | 0.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.3 € |
|---|---|
| Lowest since issue | 0.25 € |
| Spread | 0.04 € |
| Spread % | 3.77% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.3
USD
Average target price
175.5
USD
Spread / Average Target
+12.31%
- Stock Market
- Warrants
- Warrant
